Austco Healthcare
(ASX: AHC)

Investment Thesis

Coverage on Austco Healthcare (ASX: AHC) with a 12-month price target of $0.34, implying about 48% upside from the current share price of $0.23.

Austco Healthcare, based in Port Melbourne since 1986, makes nurse call and clinical communication systems: the call buttons by each bed, staff pagers and, increasingly, a mobile app that hospitals and aged care homes use to route a patient's call for help to the right nurse in seconds. It sells and installs that equipment, then earns ongoing service revenue for as long as the system stays in use, often many years, because its mission critical infrastructure is sold into a slow moving, high switching cost buyer. Once a system is wired into a hospital, replacing it means ripping out cabling and retraining clinical staff, so incumbents tend to keep their installed base for a decade or more. With around 100 staff, Austco sells across four regions, Australia and New Zealand, Asia, Europe and North America, with North America now its fastest growing market. It is small next to giants like Ascom, Ametek and Baxter, but its installed base gives it sticky, long term customer relationships.

Over the past 18 months Austco has layered a higher-margin software product, Pulse Mobile, on top of that installed base. Pulse Mobile routes a patient's call for help straight to the phone of the nurse assigned to them. Its largest US customer has now committed to rolling Pulse Mobile out across roughly 180 hospitals during calendar 2026, and that catalyst already shows up in the numbers. FY25 revenue grew 40% to $81.4m. H1 FY26 revenue grew a further 30.7% to $48.2m, with EBITDA up 60.1% and NPAT up 62.1% to $6.3m, and management has guided FY26 NPAT between $9.0m and $9.4m, up 52% to 58% on FY25. The balance sheet carries minimal debt, just $113,000 of short term borrowings as at 31 December 2025, against $15.2m of cash and a $47.2m contracted order book giving forward revenue visibility.

Despite that, AHC shares have fallen roughly 35% since their 2026 high, including a 9.6% single day drop in June on unusually heavy volume. That reset traces to a real issue rather than pure sentiment. FY25 profit margin compressed from 12% to 7.3%, with NPAT falling 16% even as revenue grew 40%, and analyst estimates for FY26 were cut through the year as the market priced in less margin recovery than it had hoped for. H1 FY26 results are the first hard evidence that the recovery is underway, with NPAT up 62% to $6.3m and EBITDA up 60%, and FY26 guidance of $9.0m to $9.4m NPAT has not been revised down since. At the current price, AHC trades at roughly 9.4 times its own guided FY26 earnings, a multiple that already reflects the margin scare rather than one that assumes the recovery now showing up in the numbers will continue.

Drivers

• A moat built on switching costs. Nurse call systems are regulated, safety critical hospital infrastructure with multi-year replacement cycles. Austco does not need to beat bigger rivals (Rauland/Ametek, Hill-Rom/Baxter, Ascom, Jeron) everywhere to keep growing. It just needs to keep winning the accounts already in its US and ANZ pipeline.
• Growth that is already contracted, not forecast. The $47.2m order book and the named 180 hospital Pulse Mobile rollout are signed commitments, not a market size slide.
• Management has real skin in the game. Insiders hold roughly 20% of the register, around $17m at the current price, and have been net buyers on market over the past year, including a direct purchase in March 2026 at a higher price than today's.
• No balance sheet risk while it scales. Low debt and $15.2m of cash means the US rollout does not require a capital raise.
• Diversifying beyond the US. Recent wins include the Warrnambool Hospital expansion in Australia, a NZ$1.1m residential aged care portfolio in New Zealand, and a multi year A$3.4m contract with Angeles Health System in Mexico, Austco's first foothold in Latin America. Growth is not resting on one customer.

Key Risks

• Customer concentration risk. The 180 hospital Pulse Mobile rollout sits with a single large US customer group. Any delay, renegotiation or loss of that relationship would directly hit the growth thesis.
• Small cap liquidity. An A$86m market cap and thin daily volumes mean the share price can move sharply on small trades or shifts in sentiment, as the recent 35% drawdown shows.
• Regulatory and compliance risk. Nurse call and clinical communication products are subject to medical device and hospital procurement regulation in each market. A compliance issue or slow approval could delay revenue recognition.
• Competitive intensity. Larger, better capitalised competitors (Ametek/Rauland, Baxter/Hill-Rom, Ascom, TeleTracking) could compete more aggressively on price or bundle nurse call with broader hospital IT platforms.
• FX exposure. A growing share of revenue is US dollar denominated as the American business scales, which adds earnings volatility from AUD/USD movements.
• Execution risk. Scaling installation and support capacity fast enough to service 180 hospitals in a single calendar year is an operational stretch for a company of this size.

Valuation

Rather than build a full DCF, I anchored valuation on Austco's own forward earnings power, since FY26 guidance gives a reasonably tight NPAT range. At the midpoint of guidance ($9.2m NPAT on 374.8m shares), FY26 EPS comes to about $0.0245, which at the current $0.23 share price is already the roughly 9.4 times forward P/E noted above.

Since there is no genuinely comparable ASX listed nurse call business to benchmark against, I anchored two scenarios to the one hard external reference point available: Bell Potter's published target of $0.45, implying about 18.4 times FY26 guided earnings. The base case assumes the market closes half that gap, and the bull case assumes it closes fully.

Conclusion

References

1. 1. Austco Healthcare Limited (2026) FY26 Trading Update (Accessed: 14 August 2026).
2. 2. Austco Healthcare Limited (2026) Half Year Results Media Release (Accessed: 14 August 2026).
3. 3. Austco Healthcare Limited (2026) Appendix 4D and 1HFY26 Accounts (Accessed: 14 August 2026).
4. 4. Austco Healthcare Limited (2025) 2025 Annual Report (Accessed: 14 August 2026).
5. 5. ASX (no date) Austco Healthcare Limited Company Page, asx.com.au/markets/company/AHC (Accessed: 14 August 2026).
6. 6. stockanalysis.com (no date) Austco Healthcare (ASX:AHC) Stock Price, Overview and Analyst Forecasts (Accessed: 14 August 2026).
7. 7. Stocks Down Under (2026) Austco Healthcare (ASX:AHC) flags 52% NPAT jump as Pulse Mobile lands 180 US hospitals (Accessed: 14 August 2026).
8. 8. Kalkine (2026) Austco Healthcare (ASX:AHC) Falls Sharply as Investors Weigh Growth and Sector Sentiment (Accessed: 14 August 2026).
9. 9. Kalkine (no date) Austco Healthcare (ASX: AHC): The Nurse-Call Tech Play (Accessed: 14 August 2026).
10. 10. Yahoo Finance (no date) Austco Healthcare Limited's (ASX:AHC) top owners are individual investors with 52% stake, while 20% is held by insiders (Accessed: 14 August 2026).

Views expressed are for learning and discussion. They are not investment advice.

Add a Thought

Something I got wrong, could have done better, or a view I haven’t considered? I’d like to hear it, and every note gets read.